Regeneron launches VEGF Trap-Eye trial & gains $20 million
September 19th 2007Regeneron Pharmaceuticals has received a $20 million milestone payment from Bayer HealthCare following dosing of the first patient in a Phase III study of the VEGF Trap-Eye for the treatment of wet age-related macular degeneration (AMD).
CCT a strong predictor of glaucoma
September 17th 2007Central corneal thickness (CCT) measurements should be included as part of a complete ocular examination, particularly in patients at risk of developing primary open angle glaucoma (POAG), according to a study conducted by the American Academy of Ophthalmology and published in the journal Ophthalmology.
Retina disease injection a thing of the past?
September 17th 2007Intravitreal injections for the treatment of retinal diseases, such as neovascular age-related macular degeneration (AMD), could be replaced by a non-invasive gel formulation, applied under the eyelid, according to a presentation made at this month's meeting of the British Royal Pharmaceutical Society in Manchester, UK.
Improving astigmatism correction with a rotation-stable, bitoric, aspherical IOL and coaxial MICS
September 11th 2007Implantation of the bitoric, aspherical intraocular lens (IOL), *Acri.Comfort 646 TLC (*Acri.Tec), is rotation-stable and associated with excellent levels of astigmatism correction in cataract patients.
Signature phaco machine offers good stability
September 11th 2007Anterior chamber fluctuations during phacoemulsification can cause an increase in retinal thickness and alterations of the blood aqueous barrier. In order to avoid these complications, it is better to use a machine that offers good anterior chamber stability.
IOL type determines complications in phakic surgery
September 11th 2007The type of phakic IOL chosen strongly governs the type of complication that is likely to occur in the long-term. Posterior, angle-supported anterior and iris supported anterior phakic IOLs all have different issues that face the surgeon.